

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1

of 9

Complete if Known

Application Number	10/720,702
Filing Date	November 24, 2003
First Named Inventor	Jacques P. Dumas
Art Unit	1621
Examiner Name	Peter G. O'Sullivan
Attorney Docket Number	5052D1(304795/69713 Div)

U. S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US- 3,478,028	11/1969	Parsons et al.	
		US- 3,753,988	08/1973	Rodway et al.	
		US- 5,089,494	02/1992	Iwase et al.	
		US- 5,324,727	06/1994	Iwase et al.	
		US- 5,849,741	12/1998	Watanabe et al.	
		US- 6,288,064	09/2001	Watanabe et al.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Foreign Patent Document Country Code ² Number "Kind Code" (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear
		EP 0534443 A1	09/1993	Mitsubishi Chem Corp.	
		EP 0722936	07/1996	Eisai Co. Ltd.	
		EP 0920868	08/1997	Eisai Co. Ltd.	
		EP 0682947	09/1997	Mitsubishi Chem Corp.	
		EP 0534443 B1	12/1998	Mitsubishi Chem Corp.	
		FR 1453897	09/1966	Robba	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). ² See Kind Code of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND**

TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 4 of 9

Complete if Known

Application Number	10/720,702
Filing Date	November 24, 2003
First Named Inventor	Jacques P. Dumas
Art Unit	1621
Examiner Name	Peter G. O'Sullivan
Attorney Docket Number	5052D1(304795/69713 Div)

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Biagi et al., Chemical Abstracts, Vol. 126:89328, 1996.	
		Biagi et al., Chemical Abstracts, Vol. 123:83329, 1995.	
		Biagli et al., Chemical Abstracts, Vol. 123:111969, 1995.	
		Monge et al., Chemical Abstracts, Vol. 120:95169, 1994.	
		Marchard et al., Chemical Abstracts, Vol. 114:42612, 1991.	
		Andersen et al., Chemical Abstracts, Vol. 112:55749, 1990.	
		Suzuki et al., Chemical Abstracts, Vol. 90:152107, 1979.	
		Mitsuhashi et al., Chemical Abstracts, Vol. 84:180170, 1976.	
		Mitsuhashi et al., Chemical Abstracts, Vol. 84:180170, 1976.	
		Sieja, Chemical Abstracts, Vol. 78:137957, 1973.	

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Sheet	5	of	9	Application Number	10/720,702
				Filing Date	November 24, 2003
				First Named Inventor	Jacques P. Dumas
				Art Unit	1621
				Examiner Name	Peter G. O'Sullivan
				Attorney Docket Number	5052D1(304795/69713 Div)

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		Pons et al., Chemical Abstracts, Vol. 71:81350, (1969)	
		Howe et al., Chemical Abstracts, Vol. 71:21922, (1969)	
		Robba et al., Chemical Abstracts, Vol. 69:10411, (1968)	
		Robba et al., Chemical Abstracts, Vol. 66:95066, (1967)	
		Robba et al., Chemical Abstracts, Vol. 66:94981, (1967)	
		Desimoni et al., Chemical Abstracts, Vol. 66:55454, (1967)	
		Chemical Abstract: 15:256197; Uenishi, Keiji et al. "Preparations of 1(3-pyridylmethyl) phthalazines as blood platelet aggregation inhibitors", Jpn. Kokai Tokkyo Koho, 6 pp 1992	
		Ferrara, N. et al., "Molecular and Biological Properties of the Vascular Endothelial Growth Factor Family of Proteins". Endocrine Reviews, 13, 18-32 (1992)	
		Neufeld, G. et al., "Vascular endothelial growth factor (VDGF) and its receptors". FASEB J., 13, 9-22 (1999).	
		Shweiki, D. et al., "Vascular Endothelial growth factor induced by hypoxia may mediate hypoxia-initated angiogenesis". Nature, 359, 843-848, (1992)	

Examiner Signature	Date Considered
-------------------------------	----------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO <h2 style="text-align: center; margin: 0;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center; margin: 0;"><i>(Use as many sheets as necessary)</i></p>			Complete if Known		
			Application Number	10/720,702	
			Filing Date	November 24, 2003	
			First Named Inventor	Jacques P. Dumas	
			Art Unit	1621	
			Examiner Name	Peter G. O'Sullivan	
			Attorney Docket Number	5052D1(304795/69713 Div)	
Sheet	6	of	9		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
		Mustonen, T. and Alitalo K., "Endothelial Receptor Tyrosine Kinases Involved in Angiogenesis". <i>Cell Biology</i> , 129, 895-898 (1995)		
		Waltenberger, J. et al., "Different Signal Transduction Properties of KDR and Flt1, Two Receptors for Vascular Endothelial Growth Factor" <i>J. Biol. Chem.</i> 269, 26988-26995, 1994		
		Seetharan, L. et al., "A unique signal transduction from FLT tyrosine kinase, a receptor for vascular endothelial growth factor VEGF". <i>Oncogene</i> , 10, 135-147 (1995)		
		Shweiki, D. et al., "Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: Implications for tumor angiogenesis". <i>Proc. Nat'l. Acad. Sci. USA</i> , 92, 768-772 (1995).		
		Grugel, S. et al., "Both v-Ha-Ras and v-Raf Stimulate Expression of the Vascular Endothelial Growth Factor in NIH 3T3 Cells." <i>J. Biol. Chem.</i> , 270, 25915-25919 (1995)		
		Rak, J. et al., "Mutant ras Oncogenes Upregulate VEGF/VPF Expression: Implications for Induction and Inhibition of Tumor Angiogenesis." <i>Cancer Research</i> 55, 4575-4580 (1995).		
		Mattern, J., et al., "Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma." <i>Brit. J. Cancer</i> , 73, 931-934 (1996)		
		Vigiletto, G. et al., "Upregulation of vascular endothelial growth factor (VDGF) and downregulation of placenta growth factor (PIGF) associated with malignancy in human thyroid tumors and cell lines". <i>Oncogene</i> , 11, 1569-1579 (1995).		
		Brown, L. et al., "Expression of Vascular Permeability Factor (Vascular Endothelial Growth Factor) and its Receptors in Breast Cancer". <i>Human Pathology</i> , 26, 86-91 (1995).		

Examiner Signature		Date Considered
--------------------	--	-----------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ² Applicant's unique citation designation number (optional). ³ See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ⁴ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁷ Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Application Number	10/720,702	
			Filing Date	November 24, 2003	
			First Named Inventor	Jacques P. Dumas	
			Art Unit	1621	
			Examiner Name	Peter G. O'Sullivan	
			Attorney Docket Number	5052D1(304795/69713 Div)	
Sheet	7	of	9		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
		Brown, L. et al., "Expression of Vascular Permeability Factor (Vascular Endothelial Growth Factor) and its Receptors in Adrenocarcinomas of the Gastrointestinal Tract". Cancer Research 53, 4727-4735 (1993)		
		Suzuki, K. et al., "Expression of Vascular Permeability Factor/Vascular Endothelial Growth Factor in Human Hepatocellular Carcinoma", Cancer Research, 56, 3004-3009 (1996)		
		Brown, L. et al., "Increased Expression of Vascular Permeability Factor (Vascular Endothelial growth Factor) and its Receptors in Kidney and Bladder Carcinomas", Am. J. Pathology, 143, 1255-1262 (1993)		
		Olson, T. et al., "Vascular Permeability Factor Gene Expression in Normal and Neoplastic Human Ovaries", Cancer Research, 54, 276-280 (1994)		
		Guidi, A. J. et al., "Vascular Permeability Factor (Vascular Endothelial Growth Factor) Expression and Angiogenesis in Cervical Neoplasia", J. Nat'l. Cancer Institute, 87, 1237-1245 (1995)		
		Hashimoto, M. et al., "Expression of Vascular Endothelial Growth Factor and its Receptor mRNA in Angiosarcoma". Laboratory Investigation, 83, 859-863, (1995)		
		Plate, Karl H. et al., "Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo". Nature, 359, 845-848 (1992)		
		Phillips, Heidi S. et al., "Intense focal expression of vascular endothelial growth factor mRNA in human intracranial neoplasms: association with regions of necrosis". Int. J. Oncology, 2, 913-919 (1993)		
		Berkman, Richard A., et al., "Expression of the Vascular Permeability Factor/Vascular Endothelial Growth Factor Gene in Central Nervous System Neoplasms", J. Clin. Invest. 91, 153-159 (1993)		

Examiner Signature	Date Considered
-----------------------	--------------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ²Applicant's unique citation designation number (optional). ³See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ⁴Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁷Applicant is to place a check mark here if English language translation is attached.

Substitute for form 1449/PTO <h2 style="text-align: center; margin: 10px 0;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center; font-size: small;">(Use as many sheets as necessary)</p>		Complete if Known <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%;">Application Number</td> <td>10/720,702</td> </tr> <tr> <td>Filing Date</td> <td>November 24, 2003</td> </tr> <tr> <td>First Named Inventor</td> <td>Jacques P. Dumas</td> </tr> <tr> <td>Art Unit</td> <td>1621</td> </tr> <tr> <td>Examiner Name</td> <td>Peter G. O'Sullivan</td> </tr> <tr> <td>Attorney Docket Number</td> <td>5052D1(304795/69713 Div)</td> </tr> </table>		Application Number	10/720,702	Filing Date	November 24, 2003	First Named Inventor	Jacques P. Dumas	Art Unit	1621	Examiner Name	Peter G. O'Sullivan	Attorney Docket Number	5052D1(304795/69713 Div)
Application Number	10/720,702														
Filing Date	November 24, 2003														
First Named Inventor	Jacques P. Dumas														
Art Unit	1621														
Examiner Name	Peter G. O'Sullivan														
Attorney Docket Number	5052D1(304795/69713 Div)														
Sheet	8	of	9												

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Kim K. Jin, et al., "Inhibition of Vascular Endothelial Growth Factor-Induced Angiogenesis Suppresses Tumour Growth in vivo," <i>Nature</i> , 362, 841-844 (1993).	
		Rockwell, P. and Goldstein, N. I., "Role of Protein Tyrosine Kinase Receptors in Cancer: Possibilities for Therapeutic Intervention", <i>Mol. and Cell. Differ.</i> , 3, 315-335 (1995).	
		Aiello, L. P., et al., "Vascular Endothelial Growth Factor in Ocular Fluid of Patients with Diabetic Retinopathy and other Retinal Disorders". <i>New England J. Med.</i> , 331, 1480-1487 (1994)	
		Pe'er, J., et al., "Hypoxia-Induced Expression of Vascular Endothelial Growth Factor by Retinal Cells is a Common Factor in Neovascularizing Ocular Diseases", <i>Lab. Invest.</i> , 72, 638-645 (1995).	
		Lopez, P. F. et al., "Transdifferentiated Retinal pigment Epithelial Cells are Immunoreactive for Vascular Endothelial Growth Factor in Surgically Excised Age-Related Macular Degeneration-Related Choroidal Neovascular Membranes". <i>Invest Ophthalmol. Vis. Sci.</i> , 37, 855-868 (1996).	
		Koch, A. E. et al., "Vascular Endothelial Growth Factor: A Cytokine Modulating Endothelial Function in Rheumatoid Arthritis," <i>J. Immunol.</i> , 152, 4149-4156 (1994).	
		Peacock, D. J., et al., "Angiogenesis Inhibition Suppresses Collagen Arthritis", <i>J. Exp. Med.</i> , 175, 1135-1138, (1992)	
		Brown, L., et al., "Increased Expression of Vascular Permeability Factor (Vascular Endothelial Growth Factor) in Bullous Pemphigoid, Dermatitis Herpetiformis, and Erythema Multiforme", <i>J. Invest. Dermatol.</i> , 194, 744-749 (1995).	
		El-Feky, S.A., "Phthalazine Derivatives from 1-Hydrazino 4-Benzyl (or Methyl) Phthalazine", <i>Egypt J. Chem.</i> , 33, 189-197 (1990).	

Examiner Signature	Date Considered
-----------------------	--------------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 909. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ² Applicant's unique citation designation number (optional). ³ See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ⁴ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁷ Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Application Number	10/720,702	
			Filing Date	November 24, 2003	
			First Named Inventor	Jacques P. Dumas	
			Art Unit	1621	
			Examiner Name	Peter G. O'Sullivan	
			Attorney Docket Number	5052D1(304795/69713 Div)	
Sheet	9	of	9		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
		Duhault, J. et al., "Etude D'Hydrazones Heterocycliques de Pyridoxal Phosphate. Comportement Coenzymatique", Bull Soc. Chim. Biol. 49, 177-0190 (1967)		
		Holava, H.M. and Partyka, R.A., "1-Substituted 4-Aryl-(or 4-Arylalkyl-) Phthalazines", J. Med. Chem. 12, 555-556 (1969)		
		Gerhardt, et al., Imidazo[4,5-d]pyridazines. IV. Synthesis Of 4,7-Disubstituted Derivatives and 1-Benzyl-2-Substituted Thio Derivatives, J. Heterocyclic Chem., 2, 247-252 (1965)		
		Malm, et al., Imidazo[4,5-d]pyridazines. III. The Synthesis of 2-Phenylimidazo[4,5-d]pyridazines. J. Heterocyclic Chem., 1, 182-185 (1964)		
		Laursen, et al., Synthesis of 2,4,7-Trichloroimidazo[4,5-d]pyridazine and Certain of its Derivatives. J. Org Chem., 27, 2500-2504 (1962)		
		Biagi, et al., 1,2,3- Triazole[4,5-d]pyridazines-IV. Preparation and Adenosine Receptor Binding of New 4 and/or 7 Amino-derivatives. Il Farmaco, 50, 99-105 (1995)		
		Majcen, et al., Pyridazines., LXIX. Annealation of an azole ring to 1,2,5-Thiadiazolo[3,4-d]pyridazine. Chem. Abstracts 83: 79175f (1975)		
		Robba et al., Thieno[2,3-d]pyridazines and thieno[3,4-d]pyridazines. Chem. Abstracts 69:10411y (1968)		
		Desimoni, et al., Polynuclear isoxazole types II. Isoxazolo[4,5-d]pyridazines. Chem. Abstracts 66: 5545u (1967)		

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached